Nav: Home

Researchers identify biomarkers of response to treatment in invasive breast cancer

December 08, 2016

CHAPEL HILL - Why do some breast cancers respond to treatment while others resist it? A study led by researchers at the University of North Carolina Lineberger Comprehensive Cancer Center may provide insight into this important question.

The researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

"We're trying to find biomarkers for resistance to trastuzumab treatment and chemotherapy," said the study's first author Maki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger. "What's the cause of response? What's the cause of resistance? That's what we are trying to identify in this genomic study."

Tanioka and his colleagues analyzed multiple biologic features of cancer cells from 213 patients treated for HER2-positive breast cancer through a National Cancer Institute cooperative group clinical trial, CALGB 40601. The biologic features included multiple kinds of genetic information such as DNA mutations, DNA copy number and RNA gene expression data. The researchers found that certain gene signatures, and either having too many, or too few, of certain genes were predictive of whether patients responded to treatment, and that combining those two features was the most effective method of predicting response.

Examining features like mutations, amplifications or deletions of genes in tumor cells, the overall subtype of the tumor, as well as indicators of immune responses helped the researchers predict response. The researchers also determined that amplification of a specific chromosome, and a particular gene called MAPK14 on that chromosome, may be a predictor of sensitivity to treatment, while deletions of other genes predicted resistance.

The researchers say the next step is to identify another set of data to validate and broaden their findings.

"HER2-positive breast cancer is genomically heterogeneous," Tanioka said. "Therefore, we need a model that incorporates all these different features. We are actively seeking a set of patient data that we can use to validate the biomarkers we have identified so we can create a comprehensive predictive model of response to allow us to better tailor treatment."
-end-
In addition to Tanioka, other authors include: C. Fan, L.A. Carey, T. Hyslop, B.N. Pitcher, J. Parker, K.A. Hoadley, N.L. Henry, S. Tolaney, C. Dang, I.E. Krop, L. Harris, D.A. Berry, E. Mardis, C.M. Perou, E.P. Winer, and C.A. Hudis.

UNC Lineberger Comprehensive Cancer Center

Related Tumor Cells Articles:

Engineered T cells may be harnessed to kill solid tumor cells
A new Tel Aviv University study finds that a form of immunotherapy used to treat the blood cancer leukemia may be effective in treating other kinds of cancer as well.
Neurons promote growth of brain tumor cells
In a current paper published in the journal 'Nature', Heidelberg-based researchers and physicians describe how neurons in the brain establish contact with aggressive glioblastomas and thus promote tumor growth / New tumor activation mechanism provides starting points for clinical trials.
Scientists develop technology to capture tumor cells
Instead of searching for a needle in a haystack, what if you were able to sweep the entire haystack to one side, leaving only the needle behind?
Tumor cells' drug addiction may be their downfall
Work by researchers at the Babraham Institute in partnership with the global biopharmaceutical company AstraZeneca shows how cancer cells' acquired resistance to anti-cancer drugs proves fatal once the treatment compound is withdrawn.
The fluid that feeds tumor cells
MIT biologists have found that the nutrient composition of the interstitial fluid that normally surrounds pancreatic tumors is different from that of the culture medium normally used to grow cancer cells.
A bad influence: the interplay between tumor cells and immune cells
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ultimately affect response to treatment.
Scientists create a complete atlas of lung tumor cells
Researchers from VIB, Leuven University and University Hospital Leuven studied thousands of healthy and cancerous lung cells to create the first comprehensive atlas of lung tumor cells.
Childhood cancer: The four survival strategies of tumor cells
Cancer cells in children tend to develop by following four main trajectories -- and two of them are linked to relapse of the disease, research led by Lund University in Sweden shows.
Mutation promts lung tumor cells to morph into gut cells
Researchers were surprised when they recently spotted a miniature gut hidden in the cells of lung tumor samples.
Versatile sensor against tumor initiating cells
The IBS researchers developed the first fluorescent sensor to visualize TICs.
More Tumor Cells News and Tumor Cells Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.